VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:VX1 • US92532F1003

394.6 EUR
-2.8 (-0.7%)
Last: Feb 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

Taking everything into account, VX1 scores 7 out of 10 in our fundamental rating. VX1 was compared to 81 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes VX1 very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year VX1 was profitable.
  • In the past year VX1 had a positive cash flow from operations.
  • VX1 had positive earnings in 4 of the past 5 years.
  • VX1 had a positive operating cash flow in 4 of the past 5 years.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • The Return On Assets of VX1 (14.78%) is better than 90.12% of its industry peers.
  • The Return On Equity of VX1 (21.22%) is better than 91.36% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 15.66%, VX1 belongs to the top of the industry, outperforming 92.59% of the companies in the same industry.
  • VX1 had an Average Return On Invested Capital over the past 3 years of 17.53%. This is significantly above the industry average of 12.03%.
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROIC 15.67%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

  • VX1's Profit Margin of 31.35% is amongst the best of the industry. VX1 outperforms 87.65% of its industry peers.
  • VX1 has a better Operating Margin (38.70%) than 93.83% of its industry peers.
  • In the last couple of years the Operating Margin of VX1 has grown nicely.
  • VX1 has a better Gross Margin (86.28%) than 79.01% of its industry peers.
  • In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), VX1 is creating some value.
  • Compared to 1 year ago, VX1 has less shares outstanding
  • The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
  • VX1 has a better debt/assets ratio than last year.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.27
WACC12.38%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of VX1 (2.36) is comparable to the rest of the industry.
  • VX1 has a Quick Ratio of 2.00. This is a normal value and indicates that VX1 is financially healthy and should not expect problems in meeting its short term obligations.
  • VX1 has a Quick ratio (2.00) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 3303.92% over the past year.
  • VX1 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.14% yearly.
  • Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 10.33% in the last year.
  • The Revenue has been growing by 21.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%

3.2 Future

  • VX1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 150.51% yearly.
  • VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.75% yearly.
EPS Next Y6350.49%
EPS Next 2Y738.46%
EPS Next 3Y328.92%
EPS Next 5Y150.51%
Revenue Next Year10.11%
Revenue Next 2Y9.4%
Revenue Next 3Y9.51%
Revenue Next 5Y9.75%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 27.03 indicates a quite expensive valuation of VX1.
  • Compared to the rest of the industry, the Price/Earnings ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 82.72% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of VX1 to the average of the S&P500 Index (28.23), we can say VX1 is valued inline with the index average.
  • VX1 is valuated rather expensively with a Price/Forward Earnings ratio of 23.02.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 81.48% of the companies listed in the same industry.
  • VX1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.01.
Industry RankSector Rank
PE 27.03
Fwd PE 23.02
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, VX1 is valued a bit cheaper than 79.01% of the companies in the same industry.
  • VX1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VX1 is cheaper than 82.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 35.68
EV/EBITDA 23.81
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • VX1 has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as VX1's earnings are expected to grow with 328.92% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y738.46%
EPS Next 3Y328.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VX1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VERTEX PHARMACEUTICALS INC

FRA:VX1 (2/10/2026, 7:00:00 PM)

394.6

-2.8 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-12
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap100.12B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.92
Price Target449.01 (13.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)5.57%
PT rev (3m)7.33%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)0.75%
EPS NY rev (1m)0.1%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE 27.03
Fwd PE 23.02
P/S 10.16
P/FCF 35.68
P/OCF 32.03
P/B 6.88
P/tB 7.54
EV/EBITDA 23.81
EPS(TTM)14.6
EY3.7%
EPS(NY)17.14
Fwd EY4.34%
FCF(TTM)11.06
FCFY2.8%
OCF(TTM)12.32
OCFY3.12%
SpS38.85
BVpS57.39
TBVpS52.36
PEG (NY)0
PEG (5Y)N/A
Graham Number137.31
Profitability
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROCE 22.25%
ROIC 15.67%
ROICexc 22.65%
ROICexgc 25.38%
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
FCFM 28.47%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 189.83%
Cap/Sales 3.25%
Interest Coverage 374.91
Cash Conversion 78.49%
Profit Quality 90.81%
Current Ratio 2.36
Quick Ratio 2
Altman-Z N/A
F-Score7
WACC12.38%
ROIC/WACC1.27
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6350.49%
EPS Next 2Y738.46%
EPS Next 3Y328.92%
EPS Next 5Y150.51%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.11%
Revenue Next 2Y9.4%
Revenue Next 3Y9.51%
Revenue Next 5Y9.75%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year824.9%
EBIT Next 3Y127.59%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 7 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Undervalued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 8 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 6350.49% in the next year.